The Therapeutic Effectiveness of 177Lu-Lilotomab in B-Cell Non-Hodgkin Lymphoma Involves Modulation of G2/M Cell Cycle Arrest

Leukemia - United Kingdom
doi 10.1038/s41375-019-0677-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

MicroRNA Dysregulation in B-Cell Non-Hodgkin Lymphoma

Blood and Lymphatic Cancer: Targets and Therapy
2013English

Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma

Asian Pacific Journal of Cancer Prevention
2018English

Rituximab in the Treatment of B-Cell Non-Hodgkin Lymphoma, Focus on Outcomes and Comparative Effectiveness

ClinicoEconomics and Outcomes Research
Health PolicyEconomicsEconometricsFinance
2010English

Zerumbone Induces G2/M Cell Cycle Arrest and Apoptosis via Mitochondrial Pathway in Jurkat Cell Line

Natural Product Communications
PharmacologyComplementaryPlant ScienceAlternative MedicineMedicineDrug Discovery
2014English

Regulation of CD20 in Rituximab-Resistant Cell Lines and B-Cell Non-Hodgkin Lymphoma

Clinical Cancer Research
Cancer ResearchOncology
2012English

BRCA1 and GADD45 Mediated G2/M Cell Cycle Arrest in Response to Antimicrotubule Agents

Oncogene
Cancer ResearchGeneticsMolecular Biology
2001English

Choosing the Appropriate Salvage Therapy for B-Cell Non-Hodgkin Lymphoma

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2018English

Autologous Stem Cell Transplantation Outcomes in Elderly Patients With B Cell Non-Hodgkin Lymphoma

British Journal of Haematology
Hematology
2015English

Emerging Role of Podocalyxin in the Progression of Mature B-Cell Non-Hodgkin Lymphoma

Cancers
Cancer ResearchOncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy